Entries by Max
APVO442: A Promising Preclinical Candidate in the Fight Against Prostate Cancer
A Seattle-based biotech, is stepping up with APVO442, a promising preclinical bispecific antibody aimed at transforming prostate cancer treatment by unleashing the body’s immune system against tumors with greater precision and fewer side effects. Built on proprietary ADAPTIR-FLEX platform, APVO442 is designed to target prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer […]
Newsletter 32/2025
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week’s newsletter is more concise, spotlighting clinical trials over preclinical research. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. For more details on […]